- April 12, 2022
Etoricoxib is an oral selective cyclo-oxygenase-2 (cox-2) inhibitor within the clinical dose range that produces dose-dependent inhibition of cox -2 without inhibition of cox-1 at doses up to 150mg daily. Etoricoxib does not inhibit gastric prostaglandin synthesis, Cyclooxygenase is responsible for the generation of prostaglandins. Two isoforms, cox-1 and cox-2, have been identified. Cox-2 is the isoform of the enzyme that has been shown to be induced by pro-inflammatory stimuli and has been postulated to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever. Cox-2 is also involved in ovulation, implantation and closure of the ductusarteriosus, regulation of renal function, and central nervous system functions (fever induction, pain perception, and cognitive function). It may also play a role in ulcer healing.
